Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H10N2O2 |
Molecular Weight | 202.2093 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=CC(OC2=CNC(=O)N=C2)=C1
InChI
InChIKey=HJQILFPVRNHTIG-UHFFFAOYSA-N
InChI=1S/C11H10N2O2/c1-8-3-2-4-9(5-8)15-10-6-12-11(14)13-7-10/h2-7H,1H3,(H,12,13,14)
Molecular Formula | C11H10N2O2 |
Molecular Weight | 202.2093 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.pharmacodia.com/yaodu/html/v1/chemicals/71def22ecb636394074c832abeed07a7.htmlCurator's Comment: Description was created based on several sources, including
http://adisinsight.springer.com/drugs/800023467
https://www.ncbi.nlm.nih.gov/pubmed/22431203
Sources: http://www.pharmacodia.com/yaodu/html/v1/chemicals/71def22ecb636394074c832abeed07a7.html
Curator's Comment: Description was created based on several sources, including
http://adisinsight.springer.com/drugs/800023467
https://www.ncbi.nlm.nih.gov/pubmed/22431203
Tolimidone, Lyn protein-tyrosine kinase stimulant, is in phase II clinical by Melior Discovery and Bukwang for the treatment of type 2 diabetes. It is also in phase II clinical by Pfizer for the treatment of ulcer. However, this research has been discontinued.
Originator
Sources: http://adisinsight.springer.com/drugs/800023467
Curator's Comment: # Pfizer
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3905 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22473614 |
63.0 nM [EC50] | ||
Target ID: CHEMBL3187 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22431203 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22431203
Mice - A single administration of MLR-1023 (Tolimidone) elicited a reduction in blood glucose levels, with a maximal response produced by a dose level of 30 mg/kg.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22473614
Incubation of Tolimidone (10 uM) with Lyn kinase elicited a
repeatable 50% increase in enzyme activity.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:15:51 GMT 2023
by
admin
on
Fri Dec 15 15:15:51 GMT 2023
|
Record UNII |
MU3JD8E9IS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29711
Created by
admin on Fri Dec 15 15:15:51 GMT 2023 , Edited by admin on Fri Dec 15 15:15:51 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
314335
Created by
admin on Fri Dec 15 15:15:51 GMT 2023 , Edited by admin on Fri Dec 15 15:15:51 GMT 2023
|
PRIMARY | |||
|
DTXSID50194786
Created by
admin on Fri Dec 15 15:15:51 GMT 2023 , Edited by admin on Fri Dec 15 15:15:51 GMT 2023
|
PRIMARY | |||
|
MU3JD8E9IS
Created by
admin on Fri Dec 15 15:15:51 GMT 2023 , Edited by admin on Fri Dec 15 15:15:51 GMT 2023
|
PRIMARY | |||
|
39065
Created by
admin on Fri Dec 15 15:15:51 GMT 2023 , Edited by admin on Fri Dec 15 15:15:51 GMT 2023
|
PRIMARY | |||
|
C152683
Created by
admin on Fri Dec 15 15:15:51 GMT 2023 , Edited by admin on Fri Dec 15 15:15:51 GMT 2023
|
PRIMARY | |||
|
SUB11157MIG
Created by
admin on Fri Dec 15 15:15:51 GMT 2023 , Edited by admin on Fri Dec 15 15:15:51 GMT 2023
|
PRIMARY | |||
|
4543
Created by
admin on Fri Dec 15 15:15:51 GMT 2023 , Edited by admin on Fri Dec 15 15:15:51 GMT 2023
|
PRIMARY | |||
|
TOLIMIDONE
Created by
admin on Fri Dec 15 15:15:51 GMT 2023 , Edited by admin on Fri Dec 15 15:15:51 GMT 2023
|
PRIMARY | |||
|
41964-07-2
Created by
admin on Fri Dec 15 15:15:51 GMT 2023 , Edited by admin on Fri Dec 15 15:15:51 GMT 2023
|
PRIMARY | |||
|
100000077755
Created by
admin on Fri Dec 15 15:15:51 GMT 2023 , Edited by admin on Fri Dec 15 15:15:51 GMT 2023
|
PRIMARY | |||
|
CHEMBL8030
Created by
admin on Fri Dec 15 15:15:51 GMT 2023 , Edited by admin on Fri Dec 15 15:15:51 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |